IgA Nephropathy Drugs Market (2026-2032)

IgA Nephropathy Drugs Market: Earlier Diagnosis, Expanding Treatment Choice and Kidney Preservation Redefine Commercial Opportunity

The Global IgA Nephropathy Drugs Market was valued at approximately USD 0.94 billion in 2025 and is projected to reach approximately USD 12.26 billion by 2032. The market is becoming increasingly important within specialty nephrology as more patients are diagnosed, disease-specific medicines move into routine treatment, and clinicians gain a broader range of options for patients with persistent proteinuria and declining kidney function.

IgA nephropathy, also known as Berger disease, is a chronic immune-mediated kidney disorder in which abnormal IgA-containing immune complexes accumulate in the glomeruli, causing inflammation, proteinuria and progressive kidney damage. The disease can remain clinically silent for years before persistent hematuria, proteinuria or deteriorating kidney function leads to specialist evaluation. In more advanced cases, patients can progress to kidney failure and require dialysis or transplantation. The long disease course is especially important because IgAN often affects younger adults, creating a substantial lifetime clinical and economic burden.

The treatment environment has changed markedly over the past several years. IgAN was historically managed largely with blood-pressure control, renin-angiotensin system inhibition, selected corticosteroid use and kidney replacement therapy for patients who progressed. That approach has expanded into a broader specialty-drug market with multiple FDA-approved disease-specific therapies and an active late-stage pipeline. Six medicines currently hold FDA approval for IgAN in the United States: Tarpeyo, Filspari, Fabhalta, Vanrafia, Voyxact and Trutakna. This expansion has changed the treatment discussion from basic kidney protection alone toward earlier disease-specific intervention in patients who remain at risk despite supportive care.

The addressable population is also becoming better defined. Recent U.S. epidemiological evidence estimates that approximately 198,887 to 208,184 people are living with IgAN, with annual incidence of roughly 1.9 to 2.2 cases per 100,000 people. The diagnosed population remains smaller because definitive diagnosis continues to rely heavily on kidney biopsy. This creates a meaningful gap between underlying prevalence and the population that has entered active nephrology care, undergone biopsy confirmation and become visible to the pharmaceutical market.

Globally, IgAN is recognized as the most common primary glomerular kidney disease, but reported prevalence and incidence vary considerably by geography. East Asia carries a particularly high disease burden, especially China and Japan, while prevalence is generally lower in North America, Europe, South America and Africa. Differences in genetic susceptibility, urine-screening programs, kidney-biopsy practices and nephrology referral patterns all influence the number of patients who are identified and formally diagnosed. The market therefore depends heavily on diagnosed prevalence and patient identification rather than total underlying prevalence alone.

Diagnosed Prevalence Is Becoming More Important Than Broad Epidemiological Estimates

Kidney biopsy remains central to diagnosis, making IgAN commercially different from many other chronic kidney diseases. Patients may have microscopic hematuria, mild proteinuria or early kidney dysfunction for years before a biopsy is performed. As a result, many individuals are not immediately included in the commercially accessible treatment population even though they may already have clinically meaningful disease.

This gap is especially important in the U.S., where modern epidemiological estimates indicate a substantially larger underlying population than earlier diagnosed-case estimates suggested. Historically, diagnosed U.S. prevalence was often placed at around 160,000 patients or lower depending on methodology. Newer epidemiology points toward approximately 200,000 people living with the disease. The difference reinforces the importance of earlier recognition, nephrology referral and confirmation of diagnosis.

The same issue applies globally. China and Japan identify more cases partly because urinary screening and nephrology evaluation are more established in some settings. European markets show substantial variation between countries based on biopsy practice, specialist access and national disease registries. For commercial forecasting, diagnosed prevalence, biopsy-confirmed disease and treatment eligibility therefore provide more useful indicators than generalized global prevalence.

Age and sex also shape the patient base. IgAN is commonly diagnosed in younger and middle-aged adults, often between 30 and 45 years of age, and men account for a larger share of cases in many populations. This demographic profile increases the long-term importance of treatment because patients may live with progressive kidney disease for decades.

Proteinuria and eGFR Are Central to Clinical Assessment and Treatment Decisions

Proteinuria is one of the most important disease-specific measures in IgAN. It is widely used to identify patients at greater risk of progression, assess treatment response and support clinical-trial endpoints. Persistent proteinuria indicates continuing glomerular injury and is associated with a greater likelihood of long-term kidney-function decline.

Current clinical practice increasingly places emphasis on reducing proteinuria while maintaining eGFR. These two measures provide complementary information: proteinuria reflects ongoing kidney injury, while eGFR indicates how much renal function remains. The balance between the two is important when determining whether a patient should remain on supportive care alone or receive additional disease-specific therapy.

The regulatory environment reflects the importance of these endpoints. Several newer IgAN therapies have received accelerated approval based on meaningful reductions in proteinuria, while longer-term studies continue to evaluate whether those improvements are accompanied by slower decline in kidney function. Voyxact provides a clear example. Its FDA approval was supported by the VISIONARY trial, where treatment produced an approximately 50% reduction in proteinuria at nine months in adults with biopsy-confirmed disease.

The growing importance of eGFR is equally significant. As more therapies achieve meaningful proteinuria reduction, differentiation is increasingly likely to depend on durability of response, preservation of kidney function, long-term safety and continued treatment benefit. For clinicians and payers, sustained renal outcomes are likely to become increasingly important as the market matures.

Supportive Kidney Care Remains the Clinical Foundation

Despite the expansion of disease-specific therapies, supportive treatment remains central to IgAN management. ACE inhibitors and angiotensin receptor blockers are widely used to lower blood pressure and reduce protein leakage. SGLT2 inhibitors are also increasingly incorporated into kidney-protective treatment strategies because of their ability to reduce chronic kidney disease progression in appropriate patients.

Lifestyle management remains relevant because IgAN is a chronic condition. Sodium restriction, weight management, smoking cessation, exercise and cardiovascular-risk control are important parts of long-term care. These measures remain necessary even when a disease-specific therapy is introduced.

The growing market for specialty drugs therefore sits on top of established kidney-protective treatment rather than replacing it. Many patients entering the specialty-drug market are already receiving background therapy but continue to show persistent proteinuria or declining kidney function. The commercially important population is therefore increasingly composed of patients whose disease remains active or progressive despite supportive care.

Six FDA-Approved Therapies Have Changed the Competitive Landscape

The U.S. market now includes six FDA-approved disease-specific treatments, creating a much more competitive environment than existed only a few years ago.

Tarpeyo, a targeted-release formulation of budesonide, was one of the first therapies to establish a disease-specific commercial market in IgAN. It initially entered through accelerated approval and later received traditional approval after longer-term kidney-function data became available.

Filspari, or sparsentan, became another important therapy and subsequently moved from accelerated to traditional FDA approval. Its commercial uptake has been particularly meaningful and has helped confirm the revenue potential of the IgAN market.

Fabhalta, or iptacopan, expanded treatment choice further and has become one of the more commercially important renal specialty products in the broader Novartis portfolio.

Vanrafia, or atrasentan, entered the U.S. market in 2025 and increased competition among therapies used for patients at risk of progressive disease.

Voyxact, or sibeprenlimab, received FDA approval in November 2025 following positive proteinuria results in the VISIONARY program.

Trutakna, or atacicept-vymj, followed in 2026, further broadening the number of disease-specific choices available to nephrologists.

The rapid sequence of approvals has changed the nature of competition. New entrants are no longer launching into a market dominated only by supportive therapy. They increasingly compete against established branded treatments, physician familiarity with existing options and payer requirements for treatment authorization.

Commercial Sales Validate IgAN as a Meaningful Specialty-Drug Market

Commercial performance from established products shows that IgAN can support significant product revenue even though the treated population is far smaller than in common chronic diseases.

Filspari generated approximately USD 322.0 million in U.S. net product sales in 2025, compared with USD 132.2 million in 2024. Travere also reported 908 new patient start forms during the fourth quarter of 2025, providing a direct indicator of continued patient uptake. This commercial performance demonstrates that the market is moving beyond early launch adoption into a more established specialty-treatment category.

Tarpeyo has also recorded substantial commercial growth. Asahi Kasei reported approximately USD 323 million in U.S. Tarpeyo sales during fiscal 2025, compared with USD 104 million recorded in fiscal 2024 following consolidation of Calliditas. The consistency of quarterly sales through fiscal 2025 indicates that Tarpeyo had developed a meaningful recurring treatment base rather than relying only on initial launch demand.

Fabhalta provides another indication of commercial scale, although its revenue is not specific to IgAN. Novartis reported approximately USD 505 million in worldwide Fabhalta sales in 2025 across its approved indications. That figure should not be interpreted as IgAN-only revenue, but it confirms the broader commercial strength of premium renal and complement-directed therapies.

These products show that treatment volume can translate into meaningful revenue even when patient numbers are modest relative to cardiovascular, metabolic or common inflammatory diseases. Specialty pricing, defined treatment populations and the need for long-term kidney protection support commercially attractive product economics.

Newer Entrants Still Need Time to Establish Their Commercial Position

Vanrafia, Voyxact and Trutakna are relatively recent entrants and therefore do not yet have mature annual sales histories comparable with Filspari or Tarpeyo.

Vanrafia entered after its April 2025 FDA approval. Voyxact followed in November 2025, while Trutakna received approval in July 2026. Their early commercial performance will be closely watched because the market is now more competitive than it was when Tarpeyo and Filspari launched.

Future uptake will depend on clinical familiarity, prescribing confidence, payer coverage, long-term outcomes and how each therapy is positioned relative to existing treatment. Mature market share is therefore likely to emerge gradually rather than immediately following regulatory approval.

Pipeline Development Keeps Competitive Pressure High

The IgAN pipeline remains active despite the growing number of approved therapies. Povetacicept, zigakibart and felzartamab are among the most closely watched late-stage programs.

Povetacicept has become one of the highest-profile pipeline candidates following Phase III development and regulatory progress. Its future commercial role will depend on final approval, label positioning, clinical outcomes and payer access.

Zigakibart remains another important late-stage candidate. Its progress will be evaluated against a market that may already contain several established specialty products by the time it reaches commercialization.

Felzartamab also adds competitive diversity. Its Phase III development gives the market another potential treatment option for patients who may not respond adequately to existing therapies.

Other investigational programs include complement-targeted agents such as sefaxersen and ravulizumab, along with additional immune-directed candidates and selected immunomodulatory approaches. The pipeline remains broad enough that competitive intensity is likely to increase through the end of the decade.

Regional Opportunity Is Shaped by Diagnosis and Treatment Access

The United States remains the most commercially mature IgA nephropathy market, supported by an estimated 198,887–208,184 prevalent patients, broad access to six FDA-approved disease-specific therapies, and established product sales. Filspari generated approximately USD 322 million in U.S. sales in 2025, while Tarpeyo generated roughly USD 323 million, confirming strong commercial uptake among diagnosed and treatment-eligible patients.

Europe has a sizeable but fragmented patient base, with registry data from 10 countries estimating approximately 47,027 prevalent patients. Kinpeygo and Filspari provide the main disease-specific treatment base, but uptake varies by country because reimbursement, health-technology assessment and specialist prescribing requirements differ across national markets.

China represents the largest patient-volume opportunity and is moving quickly toward broader treatment access. Nefecon received NMPA approval in 2023 and entered China's National Reimbursement Drug List from January 2025, while Vanrafia and additional targeted therapies have expanded treatment choice. Wider reimbursement and hospital access are likely to be more important commercial drivers than premium pricing.

Japan also represents an important high-diagnosis market, with a 2026 nationwide survey estimating approximately 103,800 IgAN patients, including about 15,646 with high disease activity. The approval of Fabhalta in September 2026 further expands the country's disease-specific treatment options.

Regional performance will therefore depend less on population size alone and more on biopsy-confirmed diagnosis, progression-risk patients, reimbursement access, specialist adoption and availability of disease-specific therapies.

Treatment Penetration Remains Below the Full Eligible Population

Although large numbers of patients already receive some form of IgAN treatment, the use of disease-specific branded therapies remains much smaller than total treated prevalence.

Many patients are managed with ACE inhibitors, ARBs, SGLT2 inhibitors, corticosteroids or other supportive approaches. Only a subset currently receives one of the newer disease-specific specialty medicines.

The gap between diagnosed prevalence and specialty-treatment penetration remains one of the most important commercial opportunities in the market. Expansion depends on nephrology referral, biopsy confirmation, persistent proteinuria, eGFR status, reimbursement, physician preference and long-term treatment persistence.

As more therapies become available, treatment rates are expected to increase, but uptake will remain selective. Physicians are likely to reserve higher-cost disease-specific therapies for patients with clinically meaningful progression risk rather than prescribing them broadly across the entire diagnosed population.

Annual Treatment Costs Raise the Commercial Value of Each Treated Patient

The economics of newer IgAN therapies differ substantially from those of traditional supportive care.

ACE inhibitors, ARBs and many corticosteroids are relatively inexpensive. Several newer specialty therapies, however, carry annual U.S. treatment costs well above USD 100,000, with some products exceeding USD 300,000 or USD 400,000 per year and certain therapies priced above USD 500,000.

This pricing structure makes the number of persistently treated patients particularly important for commercial performance. Even relatively small changes in patient starts, treatment continuation and payer coverage can materially affect product revenue.

High treatment costs also increase payer scrutiny. Reimbursement is likely to depend increasingly on evidence of durable renal benefit, manageable safety, appropriate patient selection and meaningful improvement beyond background therapy.

Economic Burden Increases Sharply as Kidney Function Declines

The economic burden of IgAN rises as patients progress through chronic kidney disease.

Early-stage disease may require regular nephrology visits, laboratory monitoring and chronic medication, but advanced disease can involve hospitalization, treatment of CKD complications, dialysis or kidney transplantation. These later stages carry significantly higher healthcare costs.

Because many patients are diagnosed early in adult life, the cumulative burden can extend over decades. Delaying loss of kidney function therefore has potential clinical and economic value well beyond short-term reductions in proteinuria.

The growing focus on kidney preservation is particularly important for payers because the financial consequences of advanced CKD are substantial. Long-term treatment decisions will increasingly be evaluated against the cost of dialysis, transplantation and ongoing management of kidney failure.

Unmet Need Has Shifted From Lack of Therapy to Better Patient Selection

The unmet-need profile in IgAN has changed quickly.

The market is no longer defined primarily by the absence of disease-specific drugs. Multiple approved therapies are now available, and additional late-stage candidates are approaching the market.

The more important unmet needs are earlier diagnosis, accurate identification of progression risk, durable kidney-function preservation, clearer treatment sequencing, long-term persistence, affordability and broader access.

Patient identification remains a major issue because biopsy confirmation is still central to diagnosis. Some patients with mild disease may remain outside specialist care until proteinuria or kidney dysfunction becomes more severe.

Treatment sequencing is another unresolved area. Physicians now have more options but limited long-term evidence on which therapy should be used first, when treatment should be changed and how patients should be managed after an incomplete response.

There is also no established precision-treatment framework comparable with biomarker-driven oncology. Clinicians currently rely mainly on biopsy findings, proteinuria, eGFR, clinical history and progression risk rather than a single validated test that determines which branded therapy should be selected for an individual patient.

Long-Term Kidney Preservation Will Shape the Next Phase of Competition

The IgA Nephropathy Drugs Market has moved from a limited treatment environment into a more competitive specialty-pharmaceutical category.

Tarpeyo and Filspari have already demonstrated that IgAN can support annual U.S. sales exceeding USD 300 million. Fabhalta has also developed into a sizeable global product across renal and hematologic indications. More recent launches including Vanrafia, Voyxact and Trutakna will determine how rapidly treatment share shifts among newer therapies.

At the same time, late-stage candidates such as povetacicept, zigakibart and felzartamab could further increase treatment choice and competitive intensity.

The market will increasingly be evaluated through clinical outcomes that matter over the long course of disease. Proteinuria reduction will remain important, but sustained eGFR preservation, delayed kidney failure, long-term safety, treatment persistence and payer acceptance are likely to carry greater weight as the market becomes more crowded.

IgAN therefore represents a growing specialty-nephrology opportunity supported by a sizeable underdiagnosed population, expanding treatment eligibility, rising use of disease-specific medicines, strong sales from established products and continued late-stage drug development.

The most important commercial opportunities are likely to remain concentrated in patients who have biopsy-confirmed disease, persistent proteinuria, clinically meaningful progression risk and sufficient kidney function to benefit from treatment. As diagnosis improves and physicians gain more therapeutic options, the number of patients entering this group is expected to increase.

The next phase of the market will be defined less by the simple availability of additional drugs and more by which therapies establish durable clinical value in routine nephrology practice. Products that preserve kidney function, remain practical for long-term use and achieve broad reimbursement are likely to secure the strongest positions as IgAN treatment continues to expand through 2032.